一、临床肿瘤杂志（2024年第74卷第5期）

September/October 2024 - Volume 74 - Issue 5（2024年9/10月第74卷第5期）
https://acsjournals.onlinelibrary.wiley.com/toc/15424863/2024/74/5

PERSPECTIVES: RESEARCH IN CONTEXT（视角：研究背景）
1. 奥希替尼延长化疗后非小细胞肺癌无进展生存期
Osimertinib prolongs progression-free lung cancer survival after chemotherapy
Mike Fillon

二、柳叶刀（2024年第404卷第10456-10459期）

（一）07 September 2024 - Volume 404 - Issue 10456（2024年9月7日第404卷第10456期）
https://www.thelancet.com/journals/lancet/issue/vol404no10456/PIIS0140-6736(24)X0036-7

COMMENT（评论）
1. 这是替卡格雷单药治疗急性冠状动脉综合征的决定性证据吗？
Is this the conclusive evidence for ticagrelor monotherapy in acute coronary syndromes?
Giulio G Stefanini* (Humanitas University, Italy)
2. 心力衰竭中的GLP-1受体激动剂：使用范围应扩展多远？
GLP-1 receptor agonists in heart failure: how far to expand use?
Camilla Hage* (Karolinska University Hospital, Sweden)
ARTICLES（研究文章）
3. 替卡格雷单药治疗与12个月双重抗血小板治疗在有和无急性冠状动脉综合征患者中的降阶：随机试验的系统综述和个体患者水平Meta分析
De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials
Marco Valgimigli* (Ente Ospedaliero Cantonale, Switzerland)
4. 塞美格鲁肽与安慰剂在心力衰竭患者中的比较，这些患者的射血分数轻度降低或保持不变：SELECT, FLOW, STEP-HFpEF, 和 STEP-HFpEF DM 随机试验的汇总分析
Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials
Mikhail N Kosiborod* (Saint Luke's Mid America Heart Institute, University of Missouri–Kansas City School of Medicine, USA)

（二）14 September 2024 - Volume 404 - Issue 10457（2024年9月14日第404卷第10457期）
https://www.thelancet.com/journals/lancet/issue/vol404no10457/PIIS0140-6736(24)X0037-9

COMMENT（评论）
1. 对于新发冠状动脉疾病，无笼解决方案的可行性如何？
How feasible is a cage-free solution for de novo coronary artery disease?
Margaret B McEntegart, Ajay J Kirtane* (Columbia University Irving Medical Center/NewYork-Presbyterian Hospital and the Cardiovascular Research Foundation, USA)
CORRESPONDENCE（通信）
2. 儿童爆炸和挤压伤的抗微生物耐药性
Antimicrobial resistance in paediatric blast and crush injuries
Emily Mayhew* (Imperial College London, UK)
3. 呼吁在印度牙科启动抗生素管理计划
A call for antibiotic stewardship initiatives for dentistry in India
Deepavalli Arumuganainar* (Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, India)
4. 生命末期抗微生物使用：公共卫生讨论中缺失的环节
Antimicrobial use at end of life: a missing link in public health discourse
Shila Pandey* (Memorial Sloan Kettering Cancer Center, USA)
5. 监狱环境中的抗微生物耐药性
Antimicrobial resistance in carceral settings
Samuel Wilk* (Tufts University School of Medicine, USA)
6. 要求关注抗生素自我用药
Demanding attention to self-medication with antibiotics
Umadevi Subramanian, Baskar Venkidasamy* (Saveetha University, India)
7. 超越细菌：抗真菌耐药性的日益威胁
Beyond bacteria: the growing threat of antifungal resistance
Norman van Rhijn, Ferry Hagen* (University of Manchester, UK; Westerdijk Fungal Biodiversity Institute, Netherlands)
ARTICLES（文章）
8. 药物涂层球囊扩张术与救援支架植入对比预期支架植入治疗新发冠状动脉病变患者（REC-CAGEFREE I）：一项开放标签、随机、非劣效试验
Drug-coated balloon angioplasty with rescue stenting versus intended stenting for the treatment of patients with de novo coronary artery lesions (REC-CAGEFREE I): an open-label, randomised, non-inferiority trial
Chao Gao, Ling Tao* (Xijing Hospital, Fourth Military Medical University, China)

（三）21 September 2024 - Volume 404 - Issue 10458（2024年9月21日第404卷第10458期）
https://www.thelancet.com/journals/lancet/issue/vol404no10458/PIIS0140-6736(24)X0038-0

COMMENT（评论）
1. 心力衰竭患者的矿皮质激素受体拮抗剂：每个患者都需要？
Mineralocorticoid receptor antagonists for every patient with heart failure
Frans H Rutten* (Utrecht University, Netherlands)
2. 1型糖尿病患者每周一次胰岛素的前景：进展更新
The promise of once-weekly insulins for type 1 diabetes: update on progress
Kaitlin M Love, Sue A Brown* (University of Virginia, USA)
3. 抗微生物耐药性处于十字路口：不采取行动的代价
Antimicrobial resistance at a crossroads: the cost of inaction
Michael Craig* (National Center for Emerging and Zoonotic Infectious Diseases, USA)
ARTICLES
4. 心力衰竭中的矿皮质激素受体拮抗剂：个体患者水平Meta分析
Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis
Pardeep S Jhund, John J V McMurray* (University of Glasgow, UK)
5. 每周一次胰岛素efseatora alfa与每天一次胰岛素degludec在1型糖尿病患者中的比较（QWINT-5）：一项3期随机非劣效试验
Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trial
Richard M Bergenstal* (HealthPartners Institute, USA)
SERIES（系列）
Respiratory Syncytial Virus 2024（2024年呼吸道合胞病毒）
6. 儿童严重呼吸道合胞病毒感染：负担、管理和新兴疗法
Severe respiratory syncytial virus infection in children: burden, management, and emerging therapies
Natalie I Mazur* (Wilhelmina Children's Hospital, Netherlands)
Respiratory Syncytial Virus 2024（2024年呼吸道合胞病毒）
7. 呼吸道合胞病毒疫苗接种和免疫预防：实现对幼儿保护的潜力
Respiratory syncytial virus vaccination and immunoprophylaxis: realising the potential for protection of young children
Clint Pecenka* (PATH, USA)

（四）28 September 2024 - Volume 404 - Issue 10459（2024年9月28日第404卷第10459期）
https://www.thelancet.com/journals/lancet/issue/vol404no10459/PIIS0140-6736(24)X0039-2

COMMENT（评论）
1. 全球抗微生物耐药性负担及2050年预测
Global burden of antimicrobial resistance and forecasts to 2050
Samuel Kariuki* (Drugs for Neglected Diseases Initiative Eastern Africa, Kenya)
2. ¹⁷⁷Lu-PSMA-617用于转移性前列腺癌：瞄准正确的位置
¹⁷⁷Lu-PSMA-617 for metastatic prostate cancer: aiming for the right spot
Joaquin Mateo* (Vall d'Hebron University Hospital Campus, Spain)
WORLD REPORT（国际报告）
3. “最后的警告信号”：XDR型伤寒
“The final warning sign”: XDR typhoid
Misbah Khan
PERSPECTIVES（视角）
Profile（人物介绍）
4. Jens Juul Holst：医生科学家和GLP-1的共同发现者
Jens Juul Holst: physician-scientist and co-discoverer of GLP-1
Geoff Watts
ARTICLES（文章）
5. 1990-2021年全球细菌抗微生物耐药性负担：系统分析及2050年预测
Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050
GBD 2021 Antimicrobial Resistance Collaborators
6. ¹⁷⁷Lu-PSMA-617与更换雄激素受体途径抑制剂治疗未接受过紫杉醇治疗的进展性转移性去势抵抗性前列腺癌（PSMAfore）：3期、随机、对照试验
¹⁷⁷Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
Michael J Morris* (Memorial Sloan Kettering Cancer Center, USA)
7. 新辅助pembrolizumab加化疗后辅助pembrolizumab与新辅助化疗单独用于早期非小细胞肺癌患者（KEYNOTE-671）：一项随机、双盲、安慰剂对照、3期试验
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
Jonathan D Spicer* (Montreal General Hospital, Canada)
CLINICAL PICTURE（临床图片）
8. 用inotuzumab ozogamicin治疗B细胞急性淋巴细胞性白血病后骨髓坏死和高炎症反应
Bone marrow necrosis and hyperinflammation after treatment with inotuzumab ozogamicin for B-cell acute lymphoblastic leukaemia
Curtis Marcoux* (Dalhousie University, Canada)

三、新英格兰医学杂志（2024年9月第391卷第9-12期）

（一）5 September 2024 - Volume 391 - No 9（2024年9月5日第391卷第9期）
https://www.nejm.org/toc/nejm/391/9

ORIGINAL ARTICLES （原创文章）
1. 多柔比星-曲贝替定联合曲贝替定维持治疗平滑肌肉瘤
Doxorubicin–Trabectedin with Trabectedin Maintenance in Leiomyosarcoma
Patricia Pautier* (Institut Gustave-Roussy, France)
2. 用于预防偏头痛的单克隆抗体针对PACAP
A Monoclonal Antibody to PACAP for Migraine Prevention
Messoud Ashina* (Copenhagen University Hospital–Rigshospitalet, Denmark)
3. 辅助静脉注射阿加曲班或依替巴肽治疗缺血性中风 
Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke
Opeolu Adeoye* (Washington University, USA)
EDITORIALS（社论）
4. 肉瘤治疗的迟到但受欢迎的进展
A Late-Arriving but Welcome Advance in Sarcoma Therapy
Robert S. Benjamin* (University of Texas M.D. Anderson Cancer Center, USA)
5. 用于偏头痛的新抗体治疗  
A New Antibody Treatment for Migraine
Elizabeth Loder (Brigham and Women’s Hospital, USA)
CORRESPONDENCE（通信）
6. Teclistamab诱导的难治性系统性红斑狼疮的缓解
Teclistamab-Induced Remission in Refractory Systemic Lupus Erythematosus
7. BCMA靶向T细胞接合器治疗自身免疫疾病
BCMA-Targeted T-Cell–Engager Therapy for Autoimmune Disease
8. CAR T细胞治疗后第二肿瘤和T细胞淋巴瘤的风险
Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy

（二）12 September 2024 - Volume 391 - No 10（2024年9月12日第391卷第10期）
https://www.nejm.org/toc/nejm/391/10

ORIGINAL ARTICLES（原创文章）
1. 新诊断慢性髓性白血病中的阿西米尼布
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia
Andreas Hochhaus* (Universitätsklinikum Jena, Germany)
2. 针对APOC3的RNA干扰剂Plozasiran治疗混合型高脂血症 
Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia
Christie M. Ballantyne* (Baylor College of Medicine and the Texas Heart Institute, USA)
3. 针对ANGPTL3的RNAi疗法Zodasiran治疗混合型高脂血症 
Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia
Robert S. Rosenson* (Mount Sinai Fuster Heart Hospital, USA)
CLINICAL DECISIONS（临床决策）
4. 婴儿胃食管反流病的药物
Medication for Gastroesophageal Reflux Disease in Infants
Julie R. Barzilay

（三）19 September 2024 - Volume 391 - No 11（2024年9月19日第391卷第11期）
https://www.nejm.org/toc/nejm/391/11

ORIGINAL ARTICLES（原创文章）
1. 减少阿片类药物过量死亡的社区基础集群随机对照试验
Community-Based Cluster-Randomized Trial to Reduce Opioid Overdose Deaths
The HEALing Communities Study Consortium
2. Axatilimab在复发或难治性慢性移植物抗宿主病（GVHD）中的应用
Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease
Daniel Wolff* (University Hospital Regensburg, Germany)
3. Pomalidomide用于遗传性出血性毛细血管扩张症（Hereditary Hemorrhagic Telangiectasia, HHT）中的鼻出血
Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia
Hanny Al-Samkari, Keith R. McCrae* (Massachusetts General Hospital, USA; Cleveland Clinic Taussig Cancer Center, USA)
EDITORIALS（社论）
4. 研究背后的科学：CSF1R阻断治疗难治性慢性移植物抗宿主病
Science behind the Study: CSF1R Blockade for Refractory Chronic Graft-versus-Host Disease
Mohamad Mohty* (Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, and Assistance Publique–Hôpitaux de Paris, Hôpital Saint
Antoine, Service d’Hématologie Clinique et Thérapie Cellulaire, Paris)

（四）26 September 2024 - Volume 391- No 12（2024年9月26日第391卷第12期）
https://www.nejm.org/toc/nejm/391/12

ORIGINAL ARTICLES（原创文章）
1. Ziresovir治疗住院婴儿呼吸道合胞病毒感染 
Ziresovir in Hospitalized Infants with Respiratory Syncytial Virus Infection
Shunying Zhao,  Jim Z. Wu* (Beijing Children’s Hospital, Capital Medical University, China; Shanghai Ark Biopharmaceutical, China)
2. 抗TL1A单克隆抗体Tulisokibart治疗溃疡性结肠炎的2期试验 
Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis
Bruce E. Sands* (Icahn School of Medicine at Mount Sinai, USA)
REVIEW ARTICLE（综述文章）
3. 神经阻滞剂恶性综合征
Neuroleptic Malignant Syndrome
Eelco F.M. Wijdicks* (Mayo Clinic Hospital, USA)
EDITORIALS（社论）
4. 逐步迈向有效的RSV感染抗病毒药物
Creeping toward Effective Antiviral Agents for RSV Infection
Edward E. Walsh (University of Rochester, USA)
5. NEJM在ESMO — Zolbetuximab治疗胃或胃食管结合部腺癌 
NEJM at ESMO — Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma
Eric J. Rubin
CORRESPONDENCE（通信）
6. Zolbetuximab治疗胃或胃食管结合部腺癌
Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma
7. Felzartamab治疗抗体介导的排斥反应
Felzartamab in Antibody-Mediated Rejection
8. Dupilumab治疗伴有嗜酸性粒细胞计数升高的COPD
Dupilumab for COPD with Elevated Eosinophil Counts

四、美国医学会杂志（2024年9月第332卷第9-12期）

（一）3 September 2024 -Volume 332 - No.9（2024年9月3日第332卷第9期）
https://jamanetwork.com/journals/jama/issue/332/9

Original Investigation（原创研究）
1. 口服抗生素与严重皮肤药物不良反应风险
Oral Antibiotics and Risk of Serious Cutaneous Adverse Drug Reactions
Erika Y. Lee (University of Toronto, Canada)
Viewpoint（观点）
2. 阿片类药物使用障碍的护理级联中的主要差距：对临床实践的影响
Major Gaps in the Cascade of Care for Opioid Use DisorderImplications for Clinical Practice
M. Allison Arwady (US Centers for Disease Control and Prevention, USA)
Medical News in Brief（医学新闻简报）
3. GLP-1 RA药物与自杀念头增加无关
GLP-1 RA Drugs Not Associated With Increased Suicidal Thoughts
Samantha Anderer

（二）10 September 2024 -Volume 332 - No.10（2024年9月10日第332卷第10期）
https://jamanetwork.com/journals/jama/issue/332/10

Original Investigation（原创研究）
1. 依地酸二钠基螯合治疗对既往心肌梗死和糖尿病患者的疗效：TACT2随机临床试验
Edetate Disodium–Based Chelation for Patients With a Previous Myocardial Infarction and DiabetesTACT2 Randomized Clinical Trial
Gervasio A. Lamas (Columbia University Division of Cardiology, Mount Sinai Medical Center, USA)
2. 子宫内暴露于纳洛酮联合丁丙诺啡与单独丁丙诺啡的比较安全性
Comparative Safety of In Utero Exposure to Buprenorphine Combined With Naloxone vs Buprenorphine Alone
Loreen Straub (Brigham and Women’s Hospital and Harvard Medical School, USA)
Review（综述）
3. 直接口服抗凝剂患者的围手术期管理综述
Perioperative Management of Patients Taking Direct Oral AnticoagulantsA Review
James D. Douketis (St. Joseph’s Healthcare Hamilton, and McMaster University, Canada)
Medical News & Perspectives（医学新闻与视角）
4. 阿尔茨海默病的血液检测、GLP-1的再利用和野火烟雾——来自AAIC的亮点
A Blood Test for Alzheimer Disease, Repurposing GLP-1s, and Wildfire Smoke—Highlights From the AAIC
Rita Rubin
Medical News in Brief（医学新闻简报）
5. 新的医疗保险指南旨在减轻美国的药物成本
New Medicare Guidelines Aim to Ease Medication Costs in US
Samantha Anderer
6. 新的检测方法可能加速败血症的抗菌药物敏感性测试
A New Assay Might Speed Antimicrobial Susceptibility Testing in Sepsis
Samantha Anderer
7. 疫苗降低了美国退伍军人长期COVID的风险，但并非完全消除
Vaccines Lowered Risk of Long COVID in US Veterans, but Not Completely
Samantha Anderer
Comment & Response（评论与回应）
8. 在比较儿童和青少年急性鼻窦炎抗生素治疗研究中结果确定天数的错误
Error in Days for Outcome Ascertainment in Study Comparing Antibiotic Treatment of Acute Sinusitis in Children and Adolescents
Timothy J. Savage (Brigham and Women’s Hospital, USA)

（三）17 September 2024 -Volume 332 - No.11（2024年9月17日第332卷第11期）https://jamanetwork.com/journals/jama/issue/332/11

Original Investigation（原创研究）
1. 乌司奴单抗治疗溃疡性结肠炎的两项随机临床试验
Risankizumab for Ulcerative ColitisTwo Randomized Clinical Trials
Edouard Louis (University Hospital CHU of Liège, Belgium)
2. 无检测远程医疗与面对面药物流产的比较
Comparison of No-Test Telehealth and In-Person Medication Abortion
Lauren J. Ralph (University of California San Francisco, USA)
Editorial（社论）
3. 单克隆抗体乌司奴单抗治疗溃疡性结肠炎
Monoclonal Antibody Risankizumab for Ulcerative Colitis
Gilaad G. Kaplan (University of Calgary, Canada)
Medical News & Perspectives（医学新闻与视角）
4. 耐药真菌的崛起为何引起国际关注
Why the Rise of This Drug-Resistant Fungus Is Raising International Concern
Maryn McKenna
Medical News in Brief（医学新闻简报）
5. 当前带状疱疹疫苗与降低痴呆风险相关
Current Shingles Vaccine Associated With Lower Risk of Dementia
Samantha Anderer
6. 研究：甲氨蝶呤可能有助于治疗关节炎疼痛
Study: Methotrexate May Have Potential to Treat Arthritis Pain
Samantha Anderer
Comment & Response（评论与回应）
7. 替代标志物与临床结果
Surrogate Markers and Clinical Outcomes
Jeffrey Siegel (US Food and Drug Administration, USA)
8. 替代标志物与临床结果
Surrogate Markers and Clinical Outcomes
Pascal Richette (Lariboisière Hospital, France)
9. 替代标志物与临床结果——回复
Surrogate Markers and Clinical Outcomes—Reply
Joshua D. Wallach (Emory University, USA)

（四）24 September 2024 -Volume 332 - No.12（2024年9月24日第332卷第12期）
https://jamanetwork.com/journals/jama/issue/332/12

Original Investigation（原创研究）
1. 在大型非心脏手术前继续与停止使用肾素-血管紧张素系统抑制剂：Stop-or-Not随机临床试验
Continuation vs Discontinuation of Renin-Angiotensin System Inhibitors Before Major Noncardiac SurgeryThe Stop-or-Not Randomized Clinical Trial
Matthieu Legrand (University of California, USA)
2. 心脏手术后钾补充与预防房颤：TIGHT K随机临床试验
Potassium Supplementation and Prevention of Atrial Fibrillation After Cardiac SurgeryThe TIGHT K Randomized Clinical Trial
Benjamin O’Brien (Charité - Universitätsmedizin Berlin, Germany)
3. 随着AHA PREVENT心血管风险方程的变化，他汀类药物和抗高血压治疗的资格预测变化
Projected Changes in Statin and Antihypertensive Therapy Eligibility With the AHA PREVENT Cardiovascular Risk Equations
James A. Diao (Harvard Medical School, USA)
Viewpoint（观点）
4. 他汀类药物用于心血管疾病一级预防——有了PREVENT，临床医生该怎么做？
Statins for Primary Prevention of Cardiovascular Disease—With PREVENT, What’s a Clinician to Do?
Sadiya S. Khan (Northwestern University Feinberg School of Medicine, USA)
JAMA Data Brief（JAMA数据简报）
5. 2型糖尿病患者GLP-1药物使用激增
GLP-1 Medication Use for Type 2 Diabetes Has Soared
Thomas A. Hegland
Medical News in Brief（医学新闻简报）
6. 世界卫生组织警告碳青霉烯耐药高毒力肺炎克雷伯菌
WHO Warns of Carbapenem-Resistant Hypervirulent Klebsiella pneumonia
Samantha Anderer
JAMA Patient Page（JAMA患者页面）
7. 百日咳是什么？
What Is Pertussis?
Elizabeth Scruggs-Wodkowski; Preeti Malani

五、自然：药物发现综述

September 2024  - Volume 23 - Issue 9（2024年9月第23卷第9期） 
https://www.nature.com/nrd/volumes/23/issues/9

Comment（评论）
1. 药物研发中的数据分析：DISRUPT-DS行业圆桌会议
Data science in pharmaceutical R&D: the DISRUPT-DS industry roundtable
Najat S. Khan, Christoph Meier (Janssen Research & Development, USA; Boston Consulting Group, USA)
News & Analysis（新闻与分析）
2. 毒蕈碱类药物为精神分裂症药物研发注入新活力
Muscarinic drugs breathe new life into schizophrenia pipeline
Katie Kingwell
News in Brief（新闻简报）
3. 礼来公司斥资32亿美元收购Morphic公司的口服整合素抑制剂治疗炎症性肠病
Eli Lilly spends $3.2 billion on Morphic’s oral integrin inhibitor for inflammatory bowel disease
Asher Mullard
4. 按患者计算药物开发成本的方法得出的估算值较低
Per-patient approach to calculating drug development costs yields lower estimate
Asher Mullard
5. TCR增强的T细胞疗法在实体癌中获得原理性临床数据
TCR-boosted T cell therapy yields proof-of-principle clinical data in solid cancer
Asher Mullard
Biobusiness Briefs（生物商业简报）
6. 全面测量生物制药研发投资
Comprehensive measurement of biopharmaceutical R&D investment
Amitabh Chandra, Noam Kirson* (Harvard University, USA; Analysis Group, Inc., USA)
From the Analyst's Couch（来自分析师的指示）
7. 药物研发中的效率、效果和生产力
Efficiency, effectiveness and productivity in pharmaceutical R&D
Alexander Roland* (IQVIA, UK)
Research Highlights（研究亮点）
8. 阿片类药物解毒剂得到增强
Opioid antidote gets a boost
Sarah Crunkhorn
9. 抗IL-11抗体显示出抗衰老特性
Anti-IL-11 antibody shows anti-ageing properties
Alex Eccleston
10. 分子胶降解剂治疗镰状细胞病
Molecular glue degrader for sickle cell disease
Katie Kingwell
11. 口服小蛋白治疗IBD
Oral miniproteins treat IBD
Sarah Crunkhorn
Reviews（综述）
12. 染色质重塑因子作为治疗靶点
Chromatin remodellers as therapeutic targets
Hayden A. Malone; Charles W. M. Roberts* (St. Jude Children’s Research Hospital, USA)
13. 正在开发的新癫痫疗法
New epilepsy therapies in development
Pavel Klein* (Mid-Atlantic Epilepsy and Sleep Center, USA)
Perspectives（观点）
14. 60年脂质纳米颗粒用于核酸递送的演变
The 60-year evolution of lipid nanoparticles for nucleic acid delivery
P. R. Cullis*; P. L. Felgner* (University of British Columbia, Canada; University of California, USA)

六、自然：免疫学综述（2024年9月第24卷第9期）

September 2024 - Volume 24 - Issue 9（2024年9月第24卷第9期）

https://www.nature.com/nri/volumes/24/issues/9

Research Highlights （研究亮点）
1. 早期使用抗生素对肺上皮的持久影响
Early life antibiotics have lasting effects on the lung epithelium
Lucy Bird
Reviews（综述）
2. 在脊椎动物和无脊椎动物中产生针对虫媒病毒的预防性免疫
Generating prophylactic immunity against arboviruses in vertebrates and invertebrates
Daniel J. Rawle, Andreas Suhrbier* (QIMR Berghofer Medical Research Institute, Australia)

七、柳叶刀：呼吸医学（2024年第12卷第9期）

September 2024 - Volume 12 - Number 9（2024年第12卷第9期）
https://www.thelancet.com/journals/lanres/issue/vol12no9/PIIS2213-2600(24)X0009-0

COMMENT（评论）
1. Foritinib，一种II型ROS1抑制剂用于非小细胞肺癌
Foritinib, a type II ROS1 inhibitor for NSCLC
Jii Bum Lee, Sai-Hong Ignatius Ou* (Yonsei University College of Medicine, South Korea; University of California Irvine School of Medicine, USA)
ARTICLES（文章）
2. Foritinib在中国晚期ROS1重排非小细胞肺癌中的应用：一项多中心、开放标签、单臂、2期研究
Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 study
Jin-Ji Yang, Yi-Long Wu* (Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, China)
REVIEW（综述）
3. 危重病人中流感相关和COVID-19相关肺曲霉病
Influenza-associated and COVID-19-associated pulmonary aspergillosis in critically ill patients
Simon Feys* (University Hospitals Leuven, Belgium)

八、英国医学期刊（2024年9月第386卷第8440-8443期）

（一）07 September 2024 - Volume 386 - Issue 8440（2024年9月07日第386卷第8440期）
https://www.bmj.com/content/386/8440

This Week（本周新闻）
1. Lecanemab：NICE表示，阿尔茨海默病药物的好处“太小”
Lecanemab: Benefits of Alzheimer’s drug are “just too small” to justify cost, says NICE
Zosia Kmietowicz; Elisabeth Mahase
2. 肾上腺功能不全：NICE表示，患者应在家中进行类固醇注射以防止住院
Adrenal insufficiency: Patients should have steroid injections at home to prevent hospital admission, says NICE
Matthew Limb
3. 百日咳：为什么孕妇的疫苗接种率急剧下降？
Whooping cough: Why have vaccination rates plummeted in pregnant women?
Emma Wilkinson
Research（研究）
4. 在40-69岁的2型糖尿病患者中，开始使用钠-葡萄糖共转运蛋白-2抑制剂与二肽基肽酶-4抑制剂后患痴呆症的风险：基于人群的队列
究
Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in adults aged 40-69 years with type 2 diabetes: population based cohort study
Anna Shin, Eun Ha Kang* (Seoul National University Bundang Hospital, Korea)
5. SGLT-2抑制剂和痴呆症
SGLT-2 inhibitors and dementia
Sung-Yun Tu, Huei-Kai Huang* (Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taiwan, China; Hualien Tzu Chi Hospital,
Buddhist Tzu Chi Medical Foundation, Taiwan, China)
Education（教育）
6. 新型和新兴的治疗重度抑郁症的方法
New and emerging treatments for major depressive disorder
Cecilia Njenga, Parashar Pravin Ramanuj* (Royal National Orthopaedic Hospital, UK)

（二）14 September 2024 - Volume 386 - Issue 8441（2024年9月14日第386卷第8441期）

https://www.bmj.com/content/386/8441

This Week（本周新闻）
1. 作为药物使用者的高潮与低谷
Highs and lows of being a drug user
Alison Shepherd
2. 药物如Ozempic如何帮助减重……以及其他一切？
How do drugs such as Ozempic work for weight loss . . . and everything else?
Marianne Guenot
Research（研究）
3. 改良牛痘安卡拉-巴伐利亚北欧疫苗对猴痘感染的有效性：模拟目标试验
Effectiveness of modified vaccinia Ankara-Bavarian Nordic vaccine against mpox infection: emulation of a target trial
Christine Navarro, Sharmistha Mishra* (Public Health Ontario, Canada; University of Toronto, Canada)
Education（教育）
4. 双膦酸盐
Bisphosphonates
Emma Billington, Gregory A Kline* (University of Calgary, Canada)
5. 减少医院的药物浪费
Reducing drug waste in hospitals
Hayley Blackburn* (University of Montana Skaggs School of Pharmacy, USA)
6. 双膦酸盐治疗的口腔并发症
An oral complication of bisphosphonate therapy
Sagar Khanna* (Cleveland Clinic, USA)
7. 抗凝和中风……以及其他故事
Anticoagulation and stroke . . . and other stories

（三）21 September 2024 - Volume 386 - Issue 8442（2024年9月21日第386卷第8442期）

https://www.bmj.com/content/386/8442

This Week（本周新闻）
1. 糖尿病：研究表明，每周一次的胰岛素注射可能和每日注射一样有效
Diabetes: Once weekly insulin could be as effective as daily injections, studies indicate
Jacqui Wise
Research（研究）
2. 成人偏头痛发作急性管理中药物干预的比较效果：系统综述和网络Meta分析
Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis

William K Karlsson, Andrea Cipriani* (Copenhagen University Hospital – Rigshospitalet, Denmark; University of Oxford, UK)

（四）28 September 2024 - Volume 386 - Issue 8443（2024年9月28日第386卷第8443期）

https://www.bmj.com/content/386/8443

Comment（评论）
1. 非甾体抗炎药可能会干扰肌肉和组织修复
Non-steroidal anti-inflammatory drugs may disrupt muscle and tissue repair
Edoardo Cervoni (Grange Surgery, UK)
Education（教育）
2. 黑色素瘤的检查点抑制剂...等其他研究
Checkpoint inhibitors for melanoma … and other research
Tom Nolan
3. 优化哮喘患者的吸入治疗
Optimising inhaled therapy for patients with asthma
Aarti Bansal* (Humber and North Yorkshire Integrated Care Board, UK)

九、自然：医学（2024年9月第30卷第9期）

September 2024 - Volume 30 - Issue 9（2024年9月第30卷第9期）
https://www.nature.com/nm/volumes/30/issues/9

Research Briefings（研究简报）
1. 蛋白质组老化标志物预测不同人群中的疾病风险和死亡率
Proteomic aging signatures predict disease risk and mortality across diverse populations
2. 减肥代谢手术与GLP-1RAs相比，心力衰竭风险较低
Bariatric metabolic surgery is associated with a lower risk for heart failure versus GLP-1RAs
Review Articles（综述文章）
3. 推进全球抗生素研究、开发和获取
Advancing global antibiotic research, development and access
Laura J. V. Piddock* (Global Antibiotic Research and Development Partnership (GARDP), Switzerland)
Articles（文章）
4. Sanfilippo综合征中的Anakinra：1/2期试验
Anakinra in Sanfilippo syndrome: a phase 1/2 trial
Lynda E. Polgreen* (Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, USA)
5. G6PD适应性选择和糖尿病并发症差异
Adaptive selection at G6PD and disparities in diabetes complications
Joseph H. Breeyear, Todd L. Edwards* (National Institute of Environmental Health Sciences, USA; Vanderbilt University Medical Center, USA)
6. 蛋白质组标志物改善常见和罕见疾病的风险预测
Proteomic signatures improve risk prediction for common and rare diseases
Julia Carrasco-Zanini* (Human Genetics and Genomics, GSK Research and Development, UK)
7. Pembrolizumab治疗晚期尿路上皮癌：KEYNOTE-361 3期试验的探索性ctDNA生物标志物分析
Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial
Thomas Powles* (Queen Mary University of London, UK)
8. Duvelisib联合罗米地平治疗复发/难治性T细胞淋巴瘤：1b/2a期试验
Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial
Steven M. Horwitz* (Memorial Sloan Kettering Cancer Center, USA)
9. 节拍化疗联合抗PD-1治疗转移性乳腺癌：贝叶斯自适应随机2期试验
Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial
Hongnan Mo, Fei Ma* (Chinese Academy of Medical Sciences and Peking Union Medical College, China)
10. 新辅助Pembrolizumab、Dabrafenib和Trametinib治疗BRAFV600突变可切除黑色素瘤：随机2期NeoTrio试验
Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial
Georgina V. Long* (The University of Sydney, Australia)
11. 新辅助化疗联合或不联合Camrelizumab治疗可切除食管鳞状细胞癌：随机3期ESCORT-NEO/NCCES01试验
Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT
NEO/NCCES01 trial
Jianjun Qin, Yin Li* (National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical
Sciences and Peking Union Medical College, China)
12. Botensilimab联合Balstilimab治疗复发/难治性微卫星稳定转移性结直肠癌：1期试验
Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial
Andrea J. Bullock, Anthony B. El-Khoueiry* (Beth Israel Deaconess Medical Center, USA; University of Southern California Norris
Comprehensive Cancer Center, USA)
13. Finotonlimab联合化疗治疗复发或转移性头颈癌：随机3期试验
Finotonlimab with chemotherapy in recurrent or metastatic head and neck cancer: a randomized phase 3 trial
Yuankai Shi* (National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, China)
14. Cabozantinib联合Nivolumab治疗转移性肾细胞癌：随机1期试验
Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
Hedyeh Ebrahimi, Sumanta K. Pal* (City of Hope Comprehensive Cancer Center, USA)
15. 采用转移性结直肠癌中个性化新抗原反应性TCR转导T细胞：2期试验中期结果
Adoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim results
Maria Parkhurst* (Surgery Branch, USA)
16. 针对病理性α-synuclein的主动免疫治疗的目标参与和免疫原性：1期安慰剂对照试验
Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial
Pepijn Eijsvogel, Jean-Cosme Dodart* (Centre for Human Drug Research and Leiden University Medical Centre, The Netherlands; Vaxxinity Inc, USA)
17. Ustekinumab治疗青少年1型糖尿病：多中心、双盲、随机2期试验
Ustekinumab for type 1 diabetes in adolescents: a multicenter, double-blind, randomized phase 2 trial
Danijela Tatovic* (Cardiff University School of Medicine, UK)
Analysis（分析）
18. CAR T细胞疗法后非复发死亡的系统综述和Meta分析
A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy
David M. Cordas dos Santos, Kai Rejeski* (Dana-Farber Cancer Institute, USA; LMU University Hospital, Germany)

十、世界精神病学

（本刊9月未更新，下一期详见2024年10月更新）